Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims
2022年3月22日 - 3:55AM
ビジネスワイヤ(英語)
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has
reached an agreement with the Attorney General of Rhode Island that
settles the state’s and its subdivisions opioid-related claims.
Under the terms of the settlement, Teva will pay Rhode Island $21
million over 13-years and will provide its recently launched,
lifesaving medicine generic Narcan® (naloxone hydrochloride nasal
spray) and a significant amount of buprenorphine naloxone
(sublingual tablets) known by the brand name Suboxone®, valued at a
combined $78.5 million (wholesale acquisition cost) over 10 years.
The settlement structure is consistent with previously announced
settlements and includes a significant component of life-saving
medicines – ample supply to meet or exceed the current need in the
state of Rhode Island for the next 10 years – while including
additional expenses from the trial that was set to start on March
16, 2022. The Company continues to actively negotiate a national
settlement.
Teva believes that today’s settlement with the state of Rhode
Island is in the best interest of those impacted by the opioid
crisis and a critical step forward in getting life-saving
treatments to the people who need them. This settlement agreement
is not an admission of any liability or wrongdoing and the Company
will continue to defend itself in court, in states where we have
not reached terms of a settlement agreement.
Buprenorphine naloxone is the primary drug used to treat opioid
addiction and considered the gold standard. Naloxone is a
life-saving medication that can reverse an overdose from opioids.1
Teva has included these products in its ongoing pursuit of a
national or narrower settlement with individual states such as the
deal announced today.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to:
- our ability to finalize the settlement with Rhode Island;
- our ability to successfully compete in the marketplace,
including: that we are substantially dependent on our generic
products; consolidation of our customer base and commercial
alliances among our customers; delays in launches of new generic
products; the increase in the number of competitors targeting
generic opportunities and seeking U.S. market exclusivity for
generic versions of significant products; our ability to develop
and commercialize biopharmaceutical products; competition for our
specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our
ability to achieve expected results from investments in our product
pipeline; our ability to develop and commercialize additional
pharmaceutical products; and the effectiveness of our patents and
other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to
incur additional indebtedness, engage in additional transactions or
make new investments, may result in a further downgrade of our
credit ratings; and our inability to raise debt or borrow funds in
amounts or on terms that are favorable to us;
- our business and operations in general, including: uncertainty
regarding the COVID-19 pandemic and the governmental and societal
responses thereto; our ability to successfully execute and maintain
the activities and efforts related to the measures we have taken or
may take in response to the COVID-19 pandemic and associated costs
therewith; effectiveness of our optimization efforts; our ability
to attract, hire and retain highly skilled personnel; manufacturing
or quality control problems; interruptions in our supply chain;
disruptions of information technology systems; breaches of our data
security; variations in intellectual property laws; challenges
associated with conducting business globally, including political
or economic instability, major hostilities or terrorism; costs and
delays resulting from the extensive pharmaceutical regulation to
which we are subject or delays in governmental processing time due
to travel and work restrictions caused by the COVID-19
pandemic;
- the effects of reforms in healthcare regulation and reductions
in pharmaceutical pricing, reimbursement and coverage; significant
sales to a limited number of customers; our ability to successfully
bid for suitable acquisition targets or licensing opportunities, or
to consummate and integrate acquisitions; and our prospects and
opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including:
failure to comply with complex legal and regulatory environments;
increased legal and regulatory action in connection with public
concern over the abuse of opioid medications and our ability to
reach a final resolution of the remaining opioid-related
litigation; scrutiny from competition and pricing authorities
around the world, including our ability to successfully defend
against the U.S. Department of Justice criminal charges of Sherman
Act violations; potential liability for patent infringement;
product liability claims; failure to comply with complex Medicare
and Medicaid reporting and payment obligations; compliance with
anti-corruption sanctions and trade control laws; environmental
risks; and the impact of ESG issues;
- other financial and economic risks, including: our exposure to
currency fluctuations and restrictions as well as credit risks;
potential impairments of our intangible assets; potential
significant increases in tax liabilities (including as a result of
potential tax reform in the United States); and the effect on our
overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our
business;
and other factors discussed in this press release and in our
Annual Report on Form 10-K for the year ended December 31, 2021,
including in the sections captioned "Risk Factors” and “Forward
Looking Statements.” Forward-looking statements speak only as of
the date on which they are made, and we assume no obligation to
update or revise any forward-looking statements or other
information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
1 https://www.cdc.gov/stopoverdose/naloxone/index.html
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220321005544/en/
IR Contacts United States Ran Meir (267) 468-4475
Israel Yael Ashman 972 (3) 914-8262
PR Contacts United States Kelley Dougherty (973)
658-0237 Yonatan Beker (973) 264 7378
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024